🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Mendus AB (publ) (STO:IMMU)
Sweden flag Sweden · Delayed Price · Currency is SEK
3.500
+0.070 (2.04%)
Nov 20, 2026, 5:29 PM CET
← View all transcripts

Earnings Call: Q3 2026

Nov 11, 2026

Summary

VITAL-CML cleared its safety stage, while early immune signals in AML and CML support continued development of vididencel. Cash was SEK 55.7 million at quarter-end, with runway into Q2 2027; key trial readouts are expected through 2027.

Operator

Welcome to Mendus Q3 2026 report presentation. We will begin with a presentation from the company speakers, CEO Dr. Erik Manting and CFO Lotta Ferm. Following the presentation, we will open up for questions. To ask a question, press star five on your telephone to enter the queue. When it is your turn to speak, press star six to unmute. I will now hand over to Dr. Erik Manting. Please go ahead.

Erik Manting
CEO, Mendus

Thank you, everyone, and also thank you everybody for joining Mendus' Q3 business update. Specifically for the people in the U.S. also, good morning, and in the next 10 minutes or so, I will give an update of where we stand as a summary of Q3. Very importantly, we have accomplished the safety and tolerability stage of the VITAL-CML trial.

VITAL-CML is the first trial we have in chronic myeloid leukemia, which is a new indication since we have in the past only been focusing on AML. The difference with AML and CML is that chronic myeloid leukemia is in principle under control with tyrosine kinase inhibitors, and therefore safety and tolerability for any new treatment is a very important aspect of treating that indication, and we have passed that hurdle in the third quarter.

Also, we are starting to get to the surface the initial data from both our CML and our AML program from the ongoing trials, and that starts to look more and more consistent with respect to the potential of our lead product, vididencel, to modulate the immune system, in the end to have better control over residual disease and to the benefit of patients.

The CADENCE trial, which is a randomized phase II-B trial in acute myeloid leukemia, or AML, in combination with a drug called oral azacitidine, is ongoing. We reached during the third quarter the first 20-patient enrollment milestone. The trial is split up in two parts. The first stage, up to 40 patients, and then we can expand it with another 100 patients. So we are now halfway the first stage of the trial, which will go up to 40 patients.

Also in the CADENCE trial, we are getting data to the surface from the research that we do on the samples we collect, and that starts to also confirm the picture that we have seen in our earlier trials in acute myeloid leukemia. We have accomplished the regulatory approval to start a new trial in acute myeloid leukemia called DIVA, and that is in a different first-line treatment setting, which is an important change in the landscape for the treatment of AML with a drug called venetoclax.

We received in the third quarter all regulatory approvals, and we are now opening up the hospitals in Australia to support this trial. Finally, yesterday we announced the expansion of our collaboration with NorthX Biologics, our manufacturer, to also start producing a cell therapy called memory NK cell therapy. Our earlier stage programs are mostly funded by grants.

We have a grant in the Netherlands called Oncode Accelerator. Now for this specific step where we set up the manufacturing infrastructure in Sweden, we have secured a grant by the Swedish innovation agency Vinnova. Handing it over to Lotta for the financial overview.

Lotta Ferm
CFO, Mendus

Yeah. Hello, everyone. Then it is time to look at the figures. Now we can see that the operating profit, there was no revenue in this quarter. The operating profit was approximately -SEK 21 million, and that is in line what we have last year for the same quarter.

The difference between this year and last year is that we have higher clinical costs, but they are offset by lower personnel costs since we did a reorganization last year. So we are spending more money in the clinic and less money in the labs and in the office nowadays. The cash position is SEK 55.7 million at the end of the quarter. If we look at the cash burn for the year, the net cash burn is, cash flow out is -SEK 9.7 million.

But then if you add that we had received a loan from Fenja of SEK 46.5 million, the net cash burn is SEK 56.4 million year to date for 2026, compared to last year when we spent SEK 64.3 million during the same period. The cash runway we have right now is extended into Q2 2027.

Erik Manting
CEO, Mendus

All right, thanks. To sum up the pipeline, we have positioned vididencel now across acute and chronic myeloid leukemia. In acute myeloid leukemia, the main strategy is to make sure we can combine with the broader first-line treatment landscape in adult AML. Again, high-intensity chemotherapy, but also less intensive first-line treatment with venetoclax and azacitidine.

We have the intention to initiate a trial in children with AML or pediatric AML, and that will be a trial exclusively in the U.S. with the MD Anderson Cancer Center. All of this, of course, shall lead to a registration trial strategy that we will define based on the data we get out of the ongoing trials and future trials that we are initiating.

In CML, we have two parallel trials to address what is considered the ultimate goal in the treatment of chronic myeloid leukemia, a functional cure or a so-called treatment-free remission, where patients can safely stop their daily treatment with tyrosine kinase inhibitors. This pipeline will come to fruition in the next 6-1 2 months.

In acute myeloid leukemia, the biggest shift in the first-line treatment landscape has been the development of a drug called venetoclax, which is a less intensive first-line treatment. More and more, it starts to show that it has similar effect as the high-intensity chemotherapy, and that is why we want to be positioned in both spectra of the field. Both post-intensive chemotherapy and in combination with venetoclax and azacitidine, and that is also the basis for our current trial strategy.

The post-chemotherapy setting was addressed by the now completed ADVANCE II trial, which was a monotherapy trial. We are now in a randomized trial called the CADENCE trial with oral azacitidine. That is the trial I just described, which is now recruiting up to 40 patients, but we will have an initial readout of that trial in the first half of next year based on the first 20 patients recruited.

We have also announced in the previous quarter that there were no product-related safety concerns, which was, of course, important based on the first 20 patients recruited. Today, we will also describe the initial immunological data we get out of the samples from that trial. Then, of course, we have started the DIVA trial.

That trial is delivering data in the course of 2027, first on safety in combination with venetoclax and azacitidine, and then in the second half of next year, the top-line data based on safety and the responses on the disease level of measurable residual disease. Of course, we also intend to start the pediatric program in the first half of next year.

What was guided was the progress that we have just reported. What the data show, including the press release that we issued this morning describing the initial translational data, is that the immune signatures and the tumor-directed immune responses that we saw in the completed ADVANCE II trial are now being confirmed in a randomized setting from the CADENCE trial.

We analyzed data from 13 patients, six patients in the control arm, seven in the treatment arm, and we started to see similar pictures as what we had seen in the ADVANCE II trial, which is that the immune system is becoming more competent in the sense that the cell types that are associated with activity against the disease are going up, and the cell types that are associated with a downward regulation of the immune system, including regulatory T cells and LAG3+ (exhausted) T cells, are going down.

That is a consistent trend that we have now seen across different trials, and that is a very encouraging signal for what we may expect in the clinic. What comes next is, like I said, the first readout of the trial in the first half of 2027, then a second readout based on the 40 patients recruited in the first half of 2028. The DIVA trial, which we have now initiated, first safety readout first half of next year, and the top-line data second half of next year.

Of course, those trials combined will define our go-to-market strategy in the course of 2028. In CML, the objective is different than in AML. In CML, which is a chronic disease, which can now today be effectively treated with a class of drugs called tyrosine kinase inhibitors, it's not so much about survival because the survival of patients is similar to that of the overall population, but it's more about quality of life.

Patients particularly struggle with the fact that they have to take these TKIs for the rest of their life to keep the disease under control, which is not only, let's say, on a day-to-day adherence challenge of having to take your drugs every day, but also with serious side effects, including resistance intolerance, but also toxicity, cardiovascular effects, for example, or endocrine effects, plus, of course, a tremendous burden for the healthcare system.

What the future of CML treatment is a functional cure where patients can live a life healthy, whereby they are safe to stop their TKIs, and where the disease doesn't come back. That's typical where immunotherapy can be effective, and that's our main objective in the treatment of CML.

To just explain in a little bit more graphic way what we're trying to do with the two trials, many patients, actually the majority of patients, accomplishes a major molecular response, which is a three-log reduction, and that's called an MR3, of the disease from diagnosis, and which is then stable. That's called chronic phase CML. But this is not an optimal level.

Actually, the level of disease can go down much further to what's called a deep molecular response, or an MR4, or even deeper, an MR4.5, or an undetectable disease. Only patients that accomplish that very deep responses, so the DMR, are, after a number of years, and that's two years in the U.S., three years in Europe, eligible to try and stop their TKIs. That's called a treatment-free remission attempt.

The problem is, of course, when you take the drugs away and when you discontinue the TKIs, the disease can come back. In the majority of patients, that actually happens already in the first 6- 12 months after stopping their TKIs. As soon as the disease is above the level of major molecular response, people have to be put back on either the existing TKI or a new TKI to get the disease down again to a deeper level.

The two things we are now addressing is, first of all, trying to get more patients into a DMR. That's actually the challenge for the majority of patients, because everybody has the disease under control, but not a lot of patients, actually three-quarters roughly, are not able to reach these very deep molecular responses, and that is addressed in the VITAL-CML trial.

Those patients have a longer history of suboptimal response. In the phase II trial, the VITAL-TFR2 trial that we are currently preparing for to start at the end of this year in the specific TFR setting, that is where we have patients that have accomplished this deep molecular response that do stop their TKIs. In this case, they will get a first set of administrations with our product, vididencel, to stimulate their immune system.

After they stop, they will get another two booster administrations, and then we will hopefully be able to show that there will be a much more improved sustained TFR, so deeper responses that continue over a longer period of time instead of patients relapsing when they stop their TKI. That is the main objective of our CML program and how that is divided over the both trials which we are now involved in.

The enrollment of the first safety tolerability stage of the VITAL-CML trial has been completed with a positive outcome. The safety tolerability was confirmed by the Data Safety Monitoring Board, and it was also the start of preparations for the phase II trial in Australia called VITAL-TFR2, and that is now ongoing with the trial expected to start at the end of this year, subject to regulatory approval by the Australian authorities.

Both trials will start to deliver data in the course of 2027, and the top-line data from the VITAL-CML trial are first, but then of course, also we start to collect data from the open-label VITAL-TFR2 trial to see if we can have an effect on the sustained TFR, as I just explained. In summary, we have now delivered on the safety tolerability.

What the first data start to show, and that is also what was released this morning in the press release, is what I also just emphasized, a positive trend in the immune competence, so the ability of the immune system to control disease, where we start to see that some negative cell types are going down and some positive cell types that are associated with disease control are going up.

To train the immune system takes time, and typically it takes roughly six months before you start to see a consistent immune response on disease. That is not only something we have observed in our trials, but also, for example, what another company, Merck and Moderna, in their collaboration were expressing when they presented their data two weeks ago in melanoma, which is a solid tumor.

The immune effect, so to train the immune system, just takes time, and then the immune system has to balance out with the residual disease until you have a balance where the immune system is actually able to control the disease. It is too early at this point in time. All the patients that were relatively stable in a suboptimal response are still at that level, except for one patient that we will describe in the next slide.

What will come next is, of course, that we will continue to collect these data. The initial immunological data that we also described higher level in the press release this morning will be presented in detail at the upcoming American Society of Hematology conference , on December 13th to be precise. The top-line results from the VITAL-CML trial are expected mid-2027.

And of course, also we want to start the phase II trial, the VITAL-TFR2 trial, in time to also start delivering data throughout the course of next year. This is the specific patient that I referred to, and this is the first patient where we start to see what we hope to see more, of course, in the VITAL-CML trial. So this was a patient that was hovering between an MR3 and an MR4, and then at the last sample that we took, which was right before the second booster injection of the product, we started to see a significant drop. This is a logarithmic scale, and this is below the line of what you call deep molecular response, so an MR4.

So what we now need to confirm, of course, is that this trend can be sustained over time and that we will hopefully also start to see it in other patients. But this is currently where we are with respect to the VITAL-CML trial and what we hope to see in that trial going forward. To summarize, the vididencel treatment results in immune activation and tumor-directed immune responses, and we have now seen it very consistently across all the indications that we have tested.

So in the different AML trial settings, we saw actually a similar pattern in the ovarian cancer trial, the ALISON trial that was completed, and now we start to see similar data coming to the surface in a randomized setting in the CADENCE trial in AML, and also already some pointers in the right direction in the CML trial that we started before the summer.

What's also helpful and important for us is that there is renewed interest in cancer vaccines and in active immunotherapies to prevent recurrence. I think if there's one important element out of the Merck and Moderna data that were presented in melanoma, it was the concept of the prevention of recurrence. This is what we have always been advocating, and I think this is just good that broader industry interest is there for these kind of therapies to prevent recurrence.

And of course, we are very happy that we are positioned competitively in the myeloid blood cancers where there is a relatively open space for this kind of treatments. The AML program is on track to establish broad positioning across the first-line treatment landscape in adult AML and also with the opportunity for the company to enter into pediatric disease. That also has a more strategic relevance because the pediatric indication is a lot smaller.

So also registration trial will be easier to handle by ourselves as a company as compared to the adult AML setting, where it will be probably beneficial to have a pharma partnership when we start to engage in registration trial. But this is a balanced strategy to create optimal value of the product and to also have an independent position to continue to move the product towards the market.

Then, of course, very importantly, initial positive safety and tolerability data support the indication expansion into CML, and that's now also being reinforced by the data that are coming to the surface in that indication. Top-line data from both the key AML and CML trials, and that's the CADENCE trial and the DIVA trial in AML, and in the CML trials, both the VITAL-CML trial and the initial data from the TFR2 trial are anticipated throughout the course of 2027, with most of the data coming together in the second half of 2027. With that, I would like to hand it over to the Q&A, and happy to answer any question.

Operator

We will now open up for questions. To ask a question, press star five on your telephone to enter the queue. When it's your turn to speak, press star six to unmute. The first question comes from Richard Ramanius at Redeye. Please go ahead.

Richard Ramanius
Analyst, Redeye

Hello. Good afternoon. I had to start one question on the VITAL-CML trial. When do you think most people in the trial will have reached around six months of treatment to be able to discern more stable response, and what percentage of patients reaching MR4 would you define as a success?

Erik Manting
CEO, Mendus

Thanks. I think that's a very relevant question, Richard. So what we mean with top-line data, which we expect by mid-next year, is that from the majority of patients, we will recruit up to 24 patients. Then, of course, assuming that the immune effect will take a few months to develop, you want to have, for as many patients as possible, six months follow-up. And that's why we guide towards mid-2027.

How you define success is, of course, different from a, let's say, clinical perspective and a personal perspective. I think from a clinical perspective, more is better, right? But I think in any case, an immune effect that will lead to more patients accomplishing DMR, and specifically if it is a sustained DMR, so where the immune effect is really delivering a long-term benefit for these patients, will have a massive impact.

I don't want to quantify if two patients or 20 patients would mean success. I think every patient that after many years of stable suboptimal response shifting to DMR, which gives them a chance to stop their TKIs, is a major win for, let's say, on a patient level. Of course, for the company, it's very important that we pick up this efficacy signal in CML.

The ultimate goal that we want to accomplish, of course, next to this group of patients that we can hopefully deliver more DMR, is the treatment-free remission setting, where we will start to look for the disease not coming back, right? Those are the two things that will come to the surface in the course of next year.

I think any positive signal in the direction of either more patients having a successful DMR versus the patients that are entering into a TFR setting, and that will hopefully have a better outcome of their TFR, will have a major impact in the field of CML, because that is going to be a game-changer. When we have a safe immunotherapy in CML that is able to deliver these durable outcomes, I think that will be a major game-changer. Right now, I think I would be a bit reluctant to guide already towards specific numbers that we would consider successful over unsuccessful.

Richard Ramanius
Analyst, Redeye

Just a very short follow-up. Do I understand correctly that patients recruited to the VITAL-CML have been on a TKI for many years?

Erik Manting
CEO, Mendus

Exactly. Yeah. Patients have to be- and this is actually the majority of patients, huh? The suboptimal responder patient population is actually a lot larger than the TFR-eligible patient population. Roughly 15%-25% of patients, depending a bit on geography, are able to meet these very deep molecular responses that make them eligible for TFR. The vast majority of patients never reach those very deep levels.

The majority of patients are in this suboptimal response range where there is enough response to keep the disease under control, also to the point of a major response in MR3, but they are never eligible for a TFR response. So, the patients that enter our trial are in that category. They have been quite stable on their level of molecular disease, but never reached DMR and never reached TFR eligibility. Every patient that we flip from that longer-term situation into a much more beneficial situation is obviously worth a lot.

Richard Ramanius
Analyst, Redeye

Okay, great. Thanks for answering my questions.

Erik Manting
CEO, Mendus

Thanks for joining, Richard.

Operator

The next question comes from Arron Aatkar at Edison Group. Please go ahead.

Arron Aatkar
Analyst, Edison Group

Good afternoon. Thanks for the presentation, and thank you for taking my questions. First of all, just looking at the NorthX collaboration, please could you expand a little bit on what opportunities this might create beyond vididencel and how these might be taken forward?

Erik Manting
CEO, Mendus

Yeah, sure. I think we've always been active in the field of NK cells. Like I said, we also have an ongoing grant in the Netherlands that allow us to use the platform that we have to expand NK cells and T cells. So it's a preclinical program. The NK cell program we have taken to the point of proof of concept and also with the initial manufacturing process established.

But if you want to be serious about a program like that, you also have to set up the manufacturing infrastructure. Now, with NorthX, we have established a manufacturing alliance in 2023. Of course, the main objective of that alliance is to have commercial quantities of vididencel for late-stage trials and in the end, commercial launch. That part was successfully completed end of 2025, so end of last year.

That's for us, of course, the basis for the collaboration. But in this case, because we were able to secure this grant from Vinnova, it also allowed us to move our NK cell program from our lab facilities into the NorthX setting, to see if we can accomplish production in a GMP facility for that specific program. Of course, it's a much earlier stage program. We think it's valuable, it's potentially best in class, but it's, let's say, a deeper pipeline program versus our clinical pipeline.

Arron Aatkar
Analyst, Edison Group

Okay, that's very helpful. Thank you. My second question now, looking at CADENCE and DIVA sort of progressing across the various AML settings, how do you see these two sort of studies shaping the eventual registrational strategy? What sort of evidence from the remaining readouts would be most helpful to sort of guide that as well as inform partner discussions?

Erik Manting
CEO, Mendus

Yeah, that's two questions in one. Let me start with the technical question and then regarding partnering. I think the scenarios that are now playing out in the first-line treatment landscape of AML is that chemotherapy has been dominating first-line treatment for, let's say, the last 40 - 50 years. It comes, of course, at a very high price because it's so toxic.

The other roughly half of patients that were considered chemo-ineligible had very poor responses to what was available at the time, which was specifically injectable form of azacitidine. Now, with venetoclax, more and more patients are able to accomplish complete remissions in that more vulnerable patient population. People have tried to experiment with venetoclax in the chemo-eligible population.

What is now coming to the surface in a larger randomized trial called the PARADIGM trial is that actually venetoclax also works very well and has similar outcomes in the fit population, the chemo-fit population. So one way or the other, there will be a shift from high-intensity chemotherapy to more venetoclax-based regimes. That is the part, of course, we want to anticipate with respect to the positioning of our product.

The registration trial scenario, there's actually three scenarios. Scenario one is we're going to stick to chemotherapy because that's still considered the most effective, and also with respect to preparation for transplant. In Europe, it is still the most dominant first-line treatment. In the U.S., that's become venetoclax, but in Europe, it's still chemotherapy.

So that could become a registration trial. We've also, of course, already had the end of phase II meeting with the FDA, and scientific advice meeting with EMA to potentially be able to carry out that program. The second scenario would be that we design a registration trial around the combination with venetoclax. So we'll have to deliver proof of concept, including safety, relatively quickly.

That's what we intend to do with the DIVA trial. That trial, also for technical reasons, will only include MRD-positive patients so that we can also quite quickly pick up early signs of efficacy. That could also be the basis for a potential registration trial. We are already preparing for the next trial to step up the patient numbers in that specific setting and to then be able to push it through into a registration trial setting.

The third scenario could be, but that's dependent on the outside world, that there will be a more granular shift between chemotherapy and venetoclax, and maybe even combinations of both drugs, or patients first being treated with chemo and then venetoclax, so that there's going to be a first-line treatment landscape, which is basically physician's choice, and that we can combine with either setting or even the combined setting.

This is why we just want to make sure that we can combine with both backbone first-line treatments to be able to optimally position for a registration trial. But that's a technical decision at a certain point in time to make, Arron, and we will do that on the basis of the data, obviously, we will get to the surface in the course of next year.

Then with respect to your question, or the part of the question about pharma partnering, of course, for us, it was very important to keep a finger on the pulse with the pharma landscape. I think there's renewed interest, to a certain extent driven by the Merck and Moderna data in solid tumors, that this kind of product is very effective in the prevention of recurrence. But also, the hem-onc space is now quite quickly picking up again.

Big deals were done in AML and CML, and also other myeloproliferative diseases. The industry is really now moving into hem-onc in a very aggressive way. For us, of course, the most important thing is to optimize the commercial value of the product, and that's why we are now positioning it across the broader AML and CML landscape.

Arron Aatkar
Analyst, Edison Group

Fantastic. Very detailed answers. Thank you. That's all for me, but congratulations again on the progress. Look forward to following on.

Erik Manting
CEO, Mendus

Likewise. Thanks, Arron, for joining.

Operator

We have no more questions at this time. As a reminder, to ask a question, press star five to enter the queue. We have no more questions in line, so I'll hand the word back to you, Erik.

Erik Manting
CEO, Mendus

Thank you, operator, and thanks, everybody, for joining, and continue to follow the story. We will keep you updated of our progress and look forward to the next interactions. Thanks so much.

Lotta Ferm
CFO, Mendus

Thank you. Bye.